$NEO News

NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evidence Across Solid Tumors And Hematologic Malignancies, At 2026 ASCO Annual Meeting

A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration

Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target

TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14

NeoGenomics Shares Jump on Earnings and Analyst Upgrades

Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25

NeoGenomics Inc (NEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

NeoGenomics Inc (NASDAQ:NEO) Crushes Estimates on Robust Clinical Growth, Launches Novel MRD Test

NeoGenomics Q1 Earnings Call Highlights

NeoGenomics (NEO) Q1 2026 Earnings Transcript

NeoGenomics (NEO) Q1 2025 Earnings Transcript

NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue

NeoGenomics Reports First Quarter 2026 Results

NeoGenomics, Inc. 2026 Q1 - Results - Earnings Call Presentation

NeoGenomics Raises FY2026 Sales Guidance from $793.000M-$801.000M to $797.000M-$803.000M vs $796.641M Est

NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate

NeoGenomics Earnings: What To Look For From NEO

Why NeoGenomics (NEO) Stock Is Trading Up Today

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration